Bio-Rad Laboratories (NYSE:BIO.B) Reaches New 52-Week High – Still a Buy?

Bio-Rad Laboratories, Inc. (NYSE:BIO.B)’s share price hit a new 52-week high on Monday . The stock traded as high as $337.00 and last traded at $337.00, with a volume of 63 shares. The stock had previously closed at $298.50.

Bio-Rad Laboratories Stock Up 8.9%

The stock’s fifty day simple moving average is $301.89 and its 200-day simple moving average is $288.01. The stock has a market cap of $9.02 billion, a P/E ratio of 55.52 and a beta of 0.93. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21.

Bio-Rad Laboratories (NYSE:BIO.B) last issued its quarterly earnings results on Thursday, April 30th. The company reported $1.89 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.